Gemdronic 5mg/100ml Injection

Zoledronic acid acts by inhibiting osteoclast-mediated bone resorption, thereby reducing bone turnover and stabilizing bone structure. The injection is administered as a slow intravenous infusion, typically over at least 15 minutes, under medical supervision to monitor for potential adverse effects such as acute phase reactions, renal impairment, hypocalcemia, and osteonecrosis of the jaw.

Prior to administration, renal function and serum calcium levels should be assessed, and patients should be adequately hydrated. Gemdronic is contraindicated in patients with severe renal impairment and hypocalcemia. Regular monitoring during treatment is essential to ensure safety and efficacy. This formulation offers a convenient dosing regimen, improving patient compliance in managing complex bone disorders.

Healthcare professionals should adhere to recommended guidelines for dosing and administration to optimize therapeutic outcomes.